Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG
- Cancer Research Campaign Beatson Laboratories, Glasgow (United Kingdom)
With the introduction of [{sup 131}I]metaiodobenzylguanidine (MIBG) therapy for the treatment of neuroblastoma, there is a need for accurate estimation of radiation dose to the urinary bladder in children. Bladder dosimetry is of particular importance when MIBG therapy is part of a combined modality treatment, either in combination with total body external beam irradiation or chemotherapy agents where additive damage to the bladder could become clinically significant. Published information on bladder doses from [{sup 131}I]MIBG is relatively scarce, but there are at least two publications which focus on bladder dosimetry in children, each using a different calculation method. We evaluated these publications in view of our initial experience with the new MIRD urodynamic model since the original publications had errors. The exercise raises doubts about the certainty of S factors previously used in children. 10 refs., 2 tabs.
- OSTI ID:
- 415046
- Journal Information:
- Journal of Nuclear Medicine, Vol. 36, Issue 8; Other Information: PBD: Aug 1995
- Country of Publication:
- United States
- Language:
- English
Similar Records
Metaiodobenzylguanidine (MIBG) labeled with /sup 123/I//sup 131/I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986
Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with 131I-mIBG, a Targeted Radionuclide